IDENTIFYING SIGNALING PATHWAYS PROSTATE TUMOR INHIBITION BY LHRH ANALOGS
IDENTIFYING SIGNALING PATHWAYS PROSTATE TUMOR INHIBITION BY LHRH ANALOGS
批准号:
7336053
负责人:
TIMOTHY TURNER
金额:
$1.15万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-06-01 至 2007-05-31
中文摘要
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得了主要资金,因此可以在其他CRISP条目中表示。所列机构为中心,不一定是研究者所在机构。在诊断时,超过一半的前列腺肿瘤已经浸润和转移。早期发现前列腺癌并不是一种安全的治疗方法,因为肿瘤可以迅速达到非依赖性。因此,我们必须了解肿瘤生长调节的生物学,以确定新的治疗靶点。促黄体激素释放激素(LHRH)及其类似物直接抑制人雄激素非依赖性前列腺细胞系(包括DU-145)的生长。这些类似物发挥其抗增殖作用的机制尚不清楚。我们提出LHRH类似物通过表皮生长因子受体(EGFR)限制促生长信号传导。之前我们已经证明:1)DU-145细胞的生长和侵袭是通过EGFR介导的,2)EGFR信号传导的细胞应答通过EGFR的直接磷酸化受到PKC介导的负性反式调节。虽然前列腺细胞中LHRH信号的数据仍不确定,但LHRH激动剂刺激乳腺肿瘤中磷脂酶C(PLC)活性的方式与LHRH在脑垂体中的方式相似。我们的模型具有PLC活性,产生二酰基甘油(DAG)并动员细胞内Ca 2+以激活蛋白激酶C(PKC)。这些发现使我们推测LHRH激动剂的抗增殖作用是通过EGFR的负衰减介导的,EGFR通过PKC的磷酸化而失活。我们建议阐明LHRH信号转导机制抑制细胞增殖和侵袭DU-145细胞在体外条件下,利用有效的LHRH类似物。我们这项研究的具体目标是确定LHRH类似物是否:1)在体外预防前列腺肿瘤生长和/或侵袭。2)影响细胞粘附特性。3)通过PKC介导的转调节实现其作用。4)改变端粒酶表达谱。该项目的成功完成将有助于阐明LHRH类似物发挥抗增殖作用的细胞内机制。这将确定细胞内通路,其中断有望限制前列腺癌的进展。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. At the time of diagnosis, more than half of prostate tumors have invaded and metastasized. Early detection of prostate cancer is not a fail-safe cure since the tumors can quickly attain hormone-independence. Thus, it is imperative that we understand the biology of tumor growth regulation to define new therapeutic targets. Luteinizing hormone releasing hormone (LHRH) and its analogs directly inhibit growth of human, androgen independent prostate cell lines, including DU-145. The mechanism by which these analogs exert their antiproliferative effects is unknown. We propose that LHRH analogs limit the pro-growth signaling through the epidermal growth factor receptor (EGFR). Previously we have shown that: 1) DU-145 cells growth and invasion are mediated through the EGFR, and 2) EGFR-signaled cell responses are subject to PKC-mediated negative transmodulation by direct phosphorylatation of the EGFR. Although the data on LHRH signaling in prostate cells is still uncertain, LHRH agonists stimulate phospholipase-C (PLC) activity in mammary tumors in a similar manner as LHRH does in the pituitary gland. Our model has PLC activity generating diacylglycerol (DAG) and mobilizing intracellular Ca2+ to activate protein kinase C PKC). These findings lead us to hypothesize that the antiproliferative effects of LHRH agonists are mediated through negative attenuation of the EGFR, which is inactivated by phosphorylation by PKC. We propose to elucidate LHRH signaling mechanism for inhibition of cell proliferation and invasion in DU-145 cells under in vitro conditions utilizing potent LHRH analogs. Our specific aims for this study are to determine whether LHRH analogs: 1) Prevent prostate tumor growth and/or invasion in vitro. 2) Influence cell adhesion profile. 3) Achieve their effects via PKC-mediated transmodulation. 4) Alter the telomerase expression profile. The successful completeion of this project will elucidate the intracellular mechanism by which LHRH analogs exert their antiproliferative effect. This will identify intracellular pathways whose disruption hold promise for restricting prostate cancer progression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigator Development Core
-
批准号:10256723
-
项目类别:
-
资助金额:$31.46万
-
财政年份:2020
-
负责人:TIMOTHY TURNER
-
依托单位:
Investigator Development Core
-
批准号:10402406
-
项目类别:
-
资助金额:$39.01万
-
财政年份:2020
-
负责人:TIMOTHY TURNER
-
依托单位:
Investigator Development Core
-
批准号:10640097
-
项目类别:
-
资助金额:$17.83万
-
财政年份:2020
-
负责人:TIMOTHY TURNER
-
依托单位:
Investigator Development Core
-
批准号:10475370
-
项目类别:
-
资助金额:$7.55万
-
财政年份:2020
-
负责人:TIMOTHY TURNER
-
依托单位:
IDENTIFYING SIGNALING PATHWAYS PROSTATE TUMOR INHIBITION BY LHRH ANALOGS
-
批准号:7959272
-
项目类别:
-
资助金额:$4.6万
-
财政年份:2009
-
负责人:TIMOTHY TURNER
-
依托单位:
IDENTIFYING SIGNALING PATHWAYS PROSTATE TUMOR INHIBITION BY LHRH ANALOGS
-
批准号:7715383
-
项目类别:
-
资助金额:$4.79万
-
财政年份:2008
-
负责人:TIMOTHY TURNER
-
依托单位:
Developmental Core
-
批准号:7425231
-
项目类别:
-
资助金额:$73.97万
-
财政年份:2007
-
负责人:TIMOTHY TURNER
-
依托单位:
IDENTIFYING SIGNALING PATHWAYS PROSTATE TUMOR INHIBITION BY LHRH ANALOGS
-
批准号:7561452
-
项目类别:
-
资助金额:$8.99万
-
财政年份:2007
-
负责人:TIMOTHY TURNER
-
依托单位:
Morehouse School of Medicine/Tuskegee University/UABCom*
-
批准号:7024818
-
项目类别:
-
资助金额:$79.29万
-
财政年份:2005
-
负责人:TIMOTHY TURNER
-
依托单位:
Administrative Core
-
批准号:7425228
-
项目类别:
-
资助金额:$13.21万
-
财政年份:2005
-
负责人:TIMOTHY TURNER
-
依托单位:
Planning and Evaluation Core
-
批准号:7425229
-
项目类别:
-
资助金额:$8.37万
-
财政年份:2005
-
负责人:TIMOTHY TURNER
-
依托单位:
Morehouse School of Medicine/Tuskegee University/UABCom*
-
批准号:7287480
-
项目类别:
-
资助金额:$27.27万
-
财政年份:2005
-
负责人:TIMOTHY TURNER
-
依托单位:
IDENTIFYING SIGNALING PATHWAYS PROSTATE TUMOR INHIBITION BY LHRH ANALOGS
-
批准号:7011433
-
项目类别:
-
资助金额:$2.62万
-
财政年份:2004
-
负责人:TIMOTHY TURNER
-
依托单位:
IN VITRO ANALYSIS OF PROSTATE TUMOR INHIBITION BY LHRH ANALOGS
-
批准号:6604779
-
项目类别:
-
资助金额:$11.63万
-
财政年份:2002
-
负责人:TIMOTHY TURNER
-
依托单位:
IN VITRO ANALYSIS OF PROSTATE TUMOR INHIBITION BY LHRH ANALOGS
-
批准号:6475062
-
项目类别:
-
资助金额:$3.95万
-
财政年份:2001
-
负责人:TIMOTHY TURNER
-
依托单位:
Tuskegee Univ/UAB Comprehensive Cancer Ctr Partnership
-
批准号:6336164
-
项目类别:
-
资助金额:$18.57万
-
财政年份:2001
-
负责人:TIMOTHY TURNER
-
依托单位:
Tuskegee Univ/UAB Comprehensive Cancer Ctr Partnership
-
批准号:6515110
-
项目类别:
-
资助金额:$21.86万
-
财政年份:2001
-
负责人:TIMOTHY TURNER
-
依托单位:
IN VITRO ANALYSIS OF PROSTATE TUMOR INHIBITION BY LHRH ANALOGS
-
批准号:6506349
-
项目类别:
-
资助金额:$11.63万
-
财政年份:2001
-
负责人:TIMOTHY TURNER
-
依托单位:
Tuskegee Univ/UAB Comprehensive Cancer Ctr Partnership
-
批准号:6634057
-
项目类别:
-
资助金额:$22.43万
-
财政年份:2001
-
负责人:TIMOTHY TURNER
-
依托单位:
IN VITRO ANALYSIS OF PROSTATE TUMOR INHIBITION BY LHRH ANALOGS
-
批准号:6593134
-
项目类别:
-
资助金额:$11.63万
-
财政年份:2001
-
负责人:TIMOTHY TURNER
-
依托单位:
国内基金
海外基金
登录
查看更多内容
USP51/Zeb1 signaling调控乳腺癌化疗耐药的病理机制及其靶向干预研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:杨爽
-
依托单位:
Zeb1/IL-8 signaling调控乳腺癌免疫微环境重塑的机制研究
-
批准号:81972454
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:杨爽
-
依托单位:
Ptch1 基因通过 Hh 信号通路(Hedgehog signaling pathway)对卵巢癌细胞增殖和凋亡的影响
-
批准号:
-
项目类别:省市级项目
-
资助金额:3.0万元
-
批准年份:2019
-
负责人:
-
依托单位:--
HBx-FXR signaling相关LncRNA在原发性肝癌中的作用及机制研究
-
批准号:81772972
-
项目类别:面上项目
-
资助金额:50.0万元
-
批准年份:2017
-
负责人:牛永东
-
依托单位:
IL-6 trans-signaling调控腹膜血管新生和通透性增高的机制研究
-
批准号:81670691
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:方炜
-
依托单位:
DDR signaling诱导Apoptin促肿瘤放射增敏治疗的研究
-
批准号:81272488
-
项目类别:面上项目
-
资助金额:70.0万元
-
批准年份:2012
-
负责人:韩苏夏
-
依托单位: